Adherence, Safety, and Feasibility of HIV Pre-Exposure Prophylaxis Among Adolescent Men Who Have Sex With Men and Transgender Women in Brazil (PrEP1519 Study)

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorDOURADO, Ines
dc.contributor.authorSOARES, Fabiane
dc.contributor.authorMAGNO, Laio
dc.contributor.authorAMORIM, Leila
dc.contributor.authorEUSTORGIO FILHO, Marcos
dc.contributor.authorLEITE, Beo
dc.contributor.authorGRECO, Dirceu
dc.contributor.authorWESTIN, Mateus
dc.contributor.authorTUPINAMBAS, Unai
dc.contributor.authorMASSA, Paula
dc.contributor.authorZUCCHI, Eliana Miura
dc.contributor.authorGRANGEIRO, Alexandre
dc.date.accessioned2024-02-15T14:53:48Z
dc.date.available2024-02-15T14:53:48Z
dc.date.issued2023
dc.description.abstractPurpose: To evaluate the adherence, safety, and feasibility of pre-exposure prophylaxis (PrEP) in real-world settings among adolescent men who have sex with men (AMSM) and transgender women (ATGW). Methods: PrEP1519 is a single-arm, multicentric demonstration cohort study of daily oral PrEP among AMSM and ATGW aged 15 to 19 years in Brazil. Study visits occurred at baseline, weeks 4, 12, and then quarterly until 96 weeks. Descriptive statistics and a mixed logistic model for longitudinal data evaluated the factors associated with high adherence. Results: One thousand sixteenAMSMand ATGWaccessed the PrEP1519 clinics. Of those, 998 (98.2%) underwent clinical triage. Forty one were diagnosed with human immunodeficiency viruses (HIV) at baseline (4.0%) and 79 (7.9%) were not eligible for PrEP. Of the 878, 795 (90.5%) enrolled in PrEP, 82 (10.3%) were lost to follow-up, and 713 were included. Therewas no significant decrease in creatinine clearance; only two participants had grade-III aspartate aminotransferase elevation. Incident HIV infection occurred in eight participants (incidence rate [IR] = 1.64 per 100 person-years [PY]): two in 15-17 years (IR = 2.24 per 100 PY) and six in 18-20 years (IR = 1.51 per 100 PY). PrEP adherencewas higher among those with more years of schooling, those reporting no difficulties in PrEP use due to side effects, and who had low HIV risk perception in the past three months. Discussion: PrEP for AMSM and ATGW was safe and feasible in real-world settings. However, a higher IR among young adolescents and a higher adherence among less vulnerable people indicate the need for greater care, considering the specificities of this age group. (c) 2023 Society for Adolescent Health and Medicine.eng
dc.description.indexMEDLINE
dc.description.indexPubMed
dc.description.indexWoS
dc.description.indexScopus
dc.description.sponsorshipUnitaid
dc.identifier.citationJOURNAL OF ADOLESCENT HEALTH, v.73, n.6, suppl.S, p.S33-S42, 2023
dc.identifier.doi10.1016/j.jadohealth.2023.09.005
dc.identifier.eissn1879-1972
dc.identifier.issn1054-139X
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/58077
dc.language.isoeng
dc.publisherELSEVIER SCIENCE INCeng
dc.relation.ispartofJournal of Adolescent Health
dc.rightsrestrictedAccesseng
dc.rights.holderCopyright ELSEVIER SCIENCE INCeng
dc.subjectPrEPeng
dc.subjectAdolescenteng
dc.subjectMen who have sex with meneng
dc.subjectTransgender womeneng
dc.subjectAdherenceeng
dc.subjectSafetyeng
dc.subjectFeasibilityeng
dc.subject.otherpreventioneng
dc.subject.wosPsychology, Developmentaleng
dc.subject.wosPublic, Environmental & Occupational Healtheng
dc.subject.wosPediatricseng
dc.titleAdherence, Safety, and Feasibility of HIV Pre-Exposure Prophylaxis Among Adolescent Men Who Have Sex With Men and Transgender Women in Brazil (PrEP1519 Study)eng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.author.externalDOURADO, Ines:Univ Fed Bahia, Inst Saude Colet, Salvador, BA, Brazil
hcfmusp.author.externalSOARES, Fabiane:Univ Fed Bahia, Inst Saude Colet, Salvador, BA, Brazil
hcfmusp.author.externalMAGNO, Laio:Univ Estado Bahia, Dept Ciencias Vida, Salvador, BA, Brazil
hcfmusp.author.externalAMORIM, Leila:Univ Fed Bahia, Inst Matemat & Estat, Salvador, BA, Brazil
hcfmusp.author.externalEUSTORGIO FILHO, Marcos:Univ Fed Bahia, Inst Matemat & Estat, Salvador, BA, Brazil
hcfmusp.author.externalLEITE, Beo:Univ Fed Bahia, Inst Saude Colet, Salvador, BA, Brazil
hcfmusp.author.externalGRECO, Dirceu:Univ Fed Minas Gerais, Fac Med, Belo Horizonte, MG, Brazil
hcfmusp.author.externalWESTIN, Mateus:Univ Fed Minas Gerais, Fac Med, Belo Horizonte, MG, Brazil
hcfmusp.author.externalTUPINAMBAS, Unai:Univ Fed Minas Gerais, Fac Med, Belo Horizonte, MG, Brazil
hcfmusp.author.externalMASSA, Paula:Univ Sao Paulo, Fac Med, Sao Paulo, SP, Brazil
hcfmusp.author.externalZUCCHI, Eliana Miura:Univ Catolica Santos, Programa Posgrad Saude Colet, Sao Paulo, Brazil
hcfmusp.citation.scopus2
hcfmusp.contributor.author-fmusphcALEXANDRE DOMINGUES GRANGEIRO
hcfmusp.description.beginpageS33
hcfmusp.description.endpageS42
hcfmusp.description.issue6
hcfmusp.description.issuesuppl S
hcfmusp.description.volume73
hcfmusp.origemWOS
hcfmusp.origem.pubmed37953006
hcfmusp.origem.scopus2-s2.0-85175543968
hcfmusp.origem.wosWOS:001105994800005
hcfmusp.publisher.cityNEW YORKeng
hcfmusp.publisher.countryUSAeng
hcfmusp.relation.referenceAnderson PL, 2018, ANTIMICROB AGENTS CH, V62, DOI 10.1128/AAC.01710-17eng
hcfmusp.relation.reference[Anonymous], 2022, Brasilia: Secretaria de Ciencia, Tecnologia, Inovacao e Insumos Estrategicos em Saude, Secretaria de Vigilancia em Saudeeng
hcfmusp.relation.reference[Anonymous], 2017, Protocolo Clinico e Diretrizes Terapeuticas para Profilaxia Pre-Exposicao (PrEP) de Risco a Infeccao pelo HIVeng
hcfmusp.relation.referenceChandra-Mouli V, 2015, J ADOLESCENT HEALTH, V56, pS1, DOI 10.1016/j.jadohealth.2014.09.015eng
hcfmusp.relation.referenceChou R, 2019, JAMA-J AM MED ASSOC, V321, P2214, DOI 10.1001/jama.2019.2591eng
hcfmusp.relation.referenceCoelho LE, 2021, AIDS BEHAV, V25, P3223, DOI 10.1007/s10461-021-03180-5eng
hcfmusp.relation.referenceDANGER, 2022, UNAIDS global AIDS Update 2022eng
hcfmusp.relation.referenceDourado I, 2023, Cad Saude Publica, V39eng
hcfmusp.relation.referenceFelisbino-Mendes Mariana Santos, 2018, Rev. bras. epidemiol., V21, pe180013, DOI 10.1590/1980-549720180013.supl.1eng
hcfmusp.relation.referenceFerraz D, 2023, ARCH SEX BEHAV, V52, P689, DOI 10.1007/s10508-022-02364-xeng
hcfmusp.relation.referenceFonner VA, 2016, AIDS, V30, P1973, DOI 10.1097/QAD.0000000000001145eng
hcfmusp.relation.referenceGill K, 2017, J INT AIDS SOC, V20, P116eng
hcfmusp.relation.referenceHaberer JE, 2015, AIDS, V29, P1277, DOI 10.1097/QAD.0000000000000647eng
hcfmusp.relation.referenceHosek SG, 2017, JAMA PEDIATR, V171, P1063, DOI 10.1001/jamapediatrics.2017.2007eng
hcfmusp.relation.referenceHosek SG, 2017, JAIDS-J ACQ IMM DEF, V74, P21, DOI 10.1097/QAI.0000000000001179eng
hcfmusp.relation.referenceKrakower D, 2019, J INT AIDS SOC, V22, DOI 10.1002/jia2.25250eng
hcfmusp.relation.referenceLall P, 2015, J INT AIDS SOC, V18, P41, DOI 10.7448/IAS.18.2.19393eng
hcfmusp.relation.referenceLandovitz RJ, 2021, NEW ENGL J MED, V385, P595, DOI 10.1056/NEJMoa2101016eng
hcfmusp.relation.referenceMagno L, 2023, ARCH SEX BEHAV, V52, P703, DOI 10.1007/s10508-022-02371-yeng
hcfmusp.relation.referenceMagno L, 2023, SEX EDUC-SEX SOC LEA, V23, P409, DOI 10.1080/14681811.2022.2047017eng
hcfmusp.relation.referenceMassa P, 2023, J MED INTERNET RES, V25, DOI 10.2196/41881eng
hcfmusp.relation.referenceRutstein SE, 2020, LANCET HIV, V7, pE721, DOI 10.1016/S2352-3018(20)30203-4eng
hcfmusp.relation.referenceSaffier IP, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2795-9eng
hcfmusp.relation.referenceSchaefer R, 2021, LANCET HIV, V8, pE502, DOI 10.1016/S2352-3018(21)00127-2eng
hcfmusp.relation.referenceShehnaz SI, 2013, EPIDEMIOL BIOSTAT PU, V10, DOI 10.2427/8724eng
hcfmusp.relation.referenceOliveira RLSE, 2023, CAD SAUDE PUBLICA, V39, DOI [10.1590/0102-311XEN176821, 10.1590/0102-311xen176821]eng
hcfmusp.relation.referenceSzwarcwald CL, 2022, REV SOC BRAS MED TRO, V55, DOI 10.1590/0037-8682-0231-2021eng
hcfmusp.relation.referenceU. D. O. H. A. H. Services, 2017, Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse eventseng
hcfmusp.relation.referenceUnited Nations, 2016, Resolution adopted by the general Assembly on 3 June 2015eng
hcfmusp.relation.referenceVan der Elst EM, 2013, AIDS BEHAV, V17, P2162, DOI 10.1007/s10461-012-0317-8eng
hcfmusp.relation.referenceVeloso VG, 2023, LANCET HIV, V10, pE84, DOI 10.1016/S2352-3018(22)00331-9eng
hcfmusp.relation.referenceYager J, 2020, JAIDS-J ACQ IMM DEF, V84, P323, DOI 10.1097/QAI.0000000000002354eng
hcfmusp.relation.referenceZhang J, 2022, LANCET HIV, V9, pE254, DOI 10.1016/S2352-3018(22)00030-3eng
hcfmusp.relation.referenceZucchi EM, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0249293eng
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublication3d094e2e-f610-41a2-978a-db373a333186
relation.isAuthorOfPublication.latestForDiscovery3d094e2e-f610-41a2-978a-db373a333186
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_DOURADO_Adherence_Safety_and_Feasibility_of_HIV_PreExposure_Prophylaxis_2023.PDF
Tamanho:
866.93 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/Outros
Artigos e Materiais de Revistas Científicas - LIM/39
Artigos e Materiais de Revistas Científicas - ODS/03